Skip to main content
Premium Trial:

Request an Annual Quote

Epitome Nets $500K SBIR Grant to Develop Protein Phosphorylation Arrays

NEW YORK (GenomeWeb News) — Epitome Biosystems has received a $500,000 Phase IIB Small Business Innovation Research grant from the National Science foundation, the company said today.
Epitome will use the cash to help it develop a technology that measures ”key tyrosine phosphorylation sites that have important roles in many cellular and drug responses,” the company said.
The technology is an antibody array that incorporates Epitome's EpiTag platform to enable researchers to qualitatively and quantitatively measure protein phosphorylation.
The firm won a Phase II SBIR grant, also for $500,000, in October 2005 that it used to develop a protein kinase that profiles cell-signaling pathways.

President Neal Gordon said the company’s products may help pharmas to develop drugs targeting diseases with abnormal signaling, such as kinase inhibitors.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.